共 50 条
Renal Cell Carcinoma Metastatic to the Pancreas: A Single Center Experience
被引:0
|作者:
Cecka, Filip
[3
]
Jon, Bohumil
[3
]
Hatlova, Jana
[5
]
Tyeova, Vera
[5
]
Neoral, Cestmir
[2
]
Ferko, Alexander
[3
]
Melichar, Bohuslav
[1
,4
]
机构:
[1] Palacky Univ, Sch Med, Dept Oncol, Teaching Hosp, Olomouc 77520, Czech Republic
[2] Palacky Univ, Sch Med, Dept Surg, Teaching Hosp, Olomouc 77520, Czech Republic
[3] Charles Univ Prague, Sch Med, Teaching Hosp, Dept Surg, Hradec Kralove, Czech Republic
[4] Charles Univ Prague, Sch Med, Teaching Hosp, Dept Radiotherapy & Oncol, Hradec Kralove, Czech Republic
[5] Charles Univ Prague, Sch Med, Teaching Hosp, Dept Pathol, Hradec Kralove, Czech Republic
关键词:
Renal cell carcinoma;
Pancreas;
Metastases;
RANDOMIZED-TRIAL;
PRIMARY MALIGNANCIES;
INTERFERON-ALPHA;
NEPHRECTOMY;
BEVACIZUMAB;
SURVIVAL;
SOLITARY;
IMMUNOTHERAPY;
SUNITINIB;
RESECTION;
D O I:
暂无
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Background/Aims: Metastatic renal cell carcinoma (RCC) is a malignant tumor characterized by great variation in the clinical course and unusual sites of metastases. Metastases to the pancreas are, in general, rare. Methodology: A retrospective chart review of patients treated a single institution. Results: Single center experience in 10 patients with this rare presentation of metastatic RCC is presented. In most cases, the course after diagnosis of RCC pancreas metastases was relatively favorable, specifically in patients treated with surgical removal of the metastases. The median survival from the diagnosis of RCC pancreas metastases was 56 months. Conclusions: The course of disease in patients with RCC pancreas metastases is often indolent. Long-term survival may be obtained after surgery even with suboptimal systemic therapy. An active therapeutic approach is warranted in these patients.
引用
收藏
页码:1529 / 1532
页数:4
相关论文